| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 A Mangia, R Santoro, N Minerva, GL Ricci, V Carretta, M Persico, F Vinelli, ... New England Journal of Medicine 352 (25), 2609-2617, 2005 | 843 | 2005 |
| Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: a retrospective study S Bruno, T Stroffolini, M Colombo, S Bollani, L Benvegnu, G Mazzella, ... Hepatology 45 (3), 579-587, 2007 | 763 | 2007 |
| Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease M Masarone, V Rosato, M Dallio, AG Gravina, A Aglitti, C Loguercio, ... Oxidative medicine and cellular longevity 2018 (1), 9547613, 2018 | 604 | 2018 |
| Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment E Gane, E Lawitz, D Pugatch, G Papatheodoridis, N Bräu, A Brown, S Pol, ... New England Journal of Medicine 377 (15), 1448-1455, 2017 | 443 | 2017 |
| The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis B Palmentieri, I De Sio, V La Mura, M Masarone, R Vecchione, S Bruno, ... Digestive and Liver Disease 38 (7), 485-489, 2006 | 421 | 2006 |
| Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert … P Loria, LE Adinolfi, S Bellentani, E Bugianesi, A Grieco, S Fargion, ... Digestive and Liver Disease 42 (4), 272-282, 2010 | 350 | 2010 |
| Non alcoholic fatty liver: epidemiology and natural history M Masarone, A Federico, L Abenavoli, C Loguercio, M Persico Reviews on recent clinical trials 9 (3), 126-133, 2014 | 340 | 2014 |
| Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels M Persico, E Persico, R Suozzo, S Conte, M de Seta, L Coppola, ... Gastroenterology 118 (4), 760-764, 2000 | 316 | 2000 |
| Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial S Bruno, P Maisonneuve, P Castellana, N Rotmensz, S Rossi, ... Bmj 330 (7497), 932, 2005 | 253 | 2005 |
| Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study GD De Palma, A Pezzullo, M Rega, M Persico, F Patrone, L Mastantuono, ... Gastrointestinal endoscopy 58 (1), 50-53, 2003 | 253 | 2003 |
| Synthesis of N1-arylidene-N2-quinolyl-and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains S Gemma, G Kukreja, C Fattorusso, M Persico, MP Romano, M Altarelli, ... Bioorganic & medicinal chemistry letters 16 (20), 5384-5388, 2006 | 248 | 2006 |
| Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: insulin resistance and response to antiviral therapy M Persico, M Capasso, E Persico, M Svelto, R Russo, D Spano, L Croce, ... Hepatology 46 (4), 1009-1015, 2007 | 202 | 2007 |
| Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 C Ferlini, L Cicchillitti, G Raspaglio, S Bartollino, S Cimitan, C Bertucci, ... Cancer research 69 (17), 6906-6914, 2009 | 182 | 2009 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 176 | 2022 |
| Prospective validation of the CLIP score: a new prognostic system for patients with ciurrhosis and hepatocellular carcinoma G Pasquale Hepatology 31, 840-845, 2000 | 172 | 2000 |
| MASK 2017: ARIA digitally‐enabled, integrated, person‐centred care for rhinitis and asthma multimorbidity using real‐world‐evidence J Bousquet, S Arnavielhe, A Bedbrook, M Bewick, D Laune, ... Clinical and translational allergy 8 (1), 45, 2018 | 171 | 2018 |
| Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology J Bousquet, PW Hellings, I Agache, F Amat, I Annesi-Maesano, ... Journal of Allergy and Clinical Immunology 143 (3), 864-879, 2019 | 166 | 2019 |
| The importance of HCV on burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. SM Sagnelli E, Stroffolini t,Mele A, Craxì A Journal of MedicalVirology 75 (4), 522 - 527, 2005 | 149* | 2005 |
| Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial CLIP group The Lancet 352 (9121), 17-20, 1998 | 142 | 1998 |
| NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome V Rosato, M Masarone, M Dallio, A Federico, A Aglitti, M Persico International journal of environmental research and public health 16 (18), 3415, 2019 | 134 | 2019 |
Antonio CraxiFull Professor of Gastroenterology and Internal Medicine, PROMISE, University of Palermo, Italy在 unipa.it 的电子邮件经过验证
